- Home
- AIFF
as 12-20-2024 4:00pm EST
Stocks
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
| Founded: | 2006 | Country: | Canada |
| Employees: | N/A | City: | KENMORE |
| Market Cap: | 26.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 59.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.32 - $15.90 | Next Earning Date: | 11-14-2024 |
| Revenue: | $74,000 | Revenue Growth: | -84.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest FIREFLY NEUROSCIENCE INC News
AIFF Breaking Stock News: Dive into AIFF Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
Simply Wall St.
a month ago
Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)
GlobeNewswire
a month ago
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
GlobeNewswire
2 months ago
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
GlobeNewswire
2 months ago
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
GlobeNewswire
2 months ago
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
GlobeNewswire
2 months ago
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
Compare AIFF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AIFF FIREFLY NEUROSCIENCE INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.